Drug Approval | May 30, 2024
Alembic Pharmaceuticals receives USFDA final approval for Sacubitril and Valsartan Tablets
Sacubitril and Valsartan Tablets are indicated to reduce the risk of cardiovascular death
Sacubitril and Valsartan Tablets are indicated to reduce the risk of cardiovascular death
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
This product will be manufactured at Lupin’s Pithampur facility in India
Farxiga is expected to have such a strong influence on the market due to the impressive results
The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
Valentas and Arnipin are indicated to reduce repeated hospitalization and the risk of cardiovascular death among adult patients with chronic mild to moderate heart failure
Sacu V is priced at Rs. 19 per tablet for a dose of 50 mg (sacubitril 24 mg + valsartan 26 mg)
Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
Subscribe To Our Newsletter & Stay Updated
